Condition (MeSH)
Infectious Mononucleosis
ClinicalTrials.gov lists 21 trials for Infectious Mononucleosis or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
21 of the 21 trials are tagged with Infectious Mononucleosis itself; the rest are tagged with a narrower condition beneath it.
When did Infectious Mononucleosis trials start? (14)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2016 | 3 |
| 2015 | 1 |
| 2008 | 1 |
Showing 10 of 14 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Infectious Mononucleosis trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 4 |
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Observational | 11 |
How many Infectious Mononucleosis trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Active, not recruiting | 2 |
| Completed | 9 |
| Terminated | 2 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Infectious Mononucleosis trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 5 |
| ModernaTX, Inc. | 2 |
| Henogen | 1 |
Which drugs are being tested for Infectious Mononucleosis? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| RITUXIMAB | 1 |
| Valomaciclovir | 1 |
| Matrix-M1 Adjuvant | 1 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| EBV gp350-Ferritin Vaccine | 2 |
| mRNA-1189 | 2 |
| Valacyclovir arrow | 1 |
| BrentuximabVedotin (BV) | 1 |
| EBV gp350-ferritin vaccine with ALFQ adjuvant | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Infectious Mononucleosis trials report? (4)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Ankle fracture | 1 | 1 |
| Mass | 1 | 1 |
| Pancreatitis | 1 | 1 |
| Testis cancer | 1 | 1 |
Which publications cover Infectious Mononucleosis? (24)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Overweight/obesity in young adulthood interacts with aspects of EBV infection in MS etiology. | Neurology(R) neuroimmunology & neuroinflammation | 2021 | Yes |
| Lasting Immunological Imprint of Primary Epstein-Barr Virus Infection With Associations to Chronic Low-Grade Inflammation and Fatigue. | Frontiers in immunology | 2021 | Yes |
| Environmental factors and risk of multiple sclerosis: Findings from meta-analyses and Mendelian randomization studies. | Multiple sclerosis (Houndmills, Basingstoke, England) | 2020 | Yes |
| Clinical practice guideline: tonsillitis II. Surgical management. | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | 2016 | Yes |
| Primary immunodeficiencies and the control of Epstein-Barr virus infection. | Annals of the New York Academy of Sciences | 2015 | Yes |
Showing 5 of 24 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.